Purpose Exploring the clinical indications of coronary artery magnetic resonance imaging(CMRA)from the perspectives of diagnostic efficacy and image quality,providing reference for the clinical application of this technology.Materials and Methods From May 2021 to March 2024,a prospective study was conducted on 110 patients who planned to undergo coronary angiography(CAG)at the First Affiliated Hospital of Henan University of Traditional Chinese Medicine.3.0T whole heart CMRA examination was performed within one week before CAG surgery,and relevant data was collected and recorded.The diagnostic efficacy of CMRA was evaluated comprehensively,the correlation between CMRA image quality and diagnostic efficacy were analyzed,and the relationship between patient factors and CMRA image quality was verified.Results Based on multi-level evaluation,CMRA had a higher diagnostic accuracy for significant coronary artery stenosis(area under the curve>0.811).The diagnostic results of CMRA were affected by image quality.When the image quality was medium or poor,the diagnostic results of CMRA and CAG were prone to inconsistency,while when the image quality was excellent or good,the diagnostic results were mostly consistent.Conclusion CMRA has similar diagnostic efficacy to CAG and high clinical application potential.The quality of CMRA images can easily affect diagnostic efficiency,and image quality should be evaluated before clinical diagnosis.

Purpose Exploring the clinical indications of coronary artery magnetic resonance imaging(CMRA)from the perspectives of diagnostic efficacy and image quality,providing reference for the clinical application of this technology.Materials and Methods From May 2021 to March 2024,a prospective study was conducted on 110 patients who planned to undergo coronary angiography(CAG)at the First Affiliated Hospital of Henan University of Traditional Chinese Medicine.3.0T whole heart CMRA examination was performed within one week before CAG surgery,and relevant data was collected and recorded.The diagnostic efficacy of CMRA was evaluated comprehensively,the correlation between CMRA image quality and diagnostic efficacy were analyzed,and the relationship between patient factors and CMRA image quality was verified.Results Based on multi-level evaluation,CMRA had a higher diagnostic accuracy for significant coronary artery stenosis(area under the curve>0.811).The diagnostic results of CMRA were affected by image quality.When the image quality was medium or poor,the diagnostic results of CMRA and CAG were prone to inconsistency,while when the image quality was excellent or good,the diagnostic results were mostly consistent.Conclusion CMRA has similar diagnostic efficacy to CAG and high clinical application potential.The quality of CMRA images can easily affect diagnostic efficiency,and image quality should be evaluated before clinical diagnosis.

A 59-year-old male patient with sigmoid colon cancer and liver metastasis received the treatments of cetuximab combined with FOLFIRI regimen (irinotecan, calcium folinate, and fluorouracil). His serum creatinine (Scr) was 82 μmol/L, and estimated glomerular filtration rate (eGFR) was 96 ml/(min·1.73 m 2) before the treatment. On the 11th day after finishing the 4th cycle of treatments, the patient developed nausea and vomiting. Laboratory tests showed Scr 221 μmol/L, eGFR 29 ml/(min·1.73 m 2), serum albumin 29.0 g/L, urinary protein (+++), and 24 hour urine protein quantified 8.88 g. He was diagnosed as having nephrotic syndrome complicated with acute kidney injury, which was considered to be related to cetuximab. The drug was stopped and symptomatic treatments such as anti-inflammatory, anticoagulation and kidney protection were given. After 14 days, laboratory tests showed no proteinuria, Scr 156 μmol/L, and eGFR 44 ml/(min·1.73 m 2). Prednisone acetate tablet 50 mg were orally administered once daily. Fifty-nine days later, his Scr was 142 μmol/L, and eGFR was 49 ml/(min·1.73 m 2). Chemotherapy was suspended and cetuximab was discontinued permanently.

A 59-year-old male patient with sigmoid colon cancer and liver metastasis received the treatments of cetuximab combined with FOLFIRI regimen (irinotecan, calcium folinate, and fluorouracil). His serum creatinine (Scr) was 82 μmol/L, and estimated glomerular filtration rate (eGFR) was 96 ml/(min·1.73 m 2) before the treatment. On the 11th day after finishing the 4th cycle of treatments, the patient developed nausea and vomiting. Laboratory tests showed Scr 221 μmol/L, eGFR 29 ml/(min·1.73 m 2), serum albumin 29.0 g/L, urinary protein (+++), and 24 hour urine protein quantified 8.88 g. He was diagnosed as having nephrotic syndrome complicated with acute kidney injury, which was considered to be related to cetuximab. The drug was stopped and symptomatic treatments such as anti-inflammatory, anticoagulation and kidney protection were given. After 14 days, laboratory tests showed no proteinuria, Scr 156 μmol/L, and eGFR 44 ml/(min·1.73 m 2). Prednisone acetate tablet 50 mg were orally administered once daily. Fifty-nine days later, his Scr was 142 μmol/L, and eGFR was 49 ml/(min·1.73 m 2). Chemotherapy was suspended and cetuximab was discontinued permanently.

Objective:To preliminarily evaluate the lumen gain of sonodynamic therapy (SDT) mediated by sinoporphyrin sodium at carotid and femoral atherosclerotic plaque sites, and to assess whether concomitant statin use, lesion location, plaque echogenicity/type, and baseline stenosis severity modify the therapeutic response.Methods:This single-center, prospective, exploratory pilot clinical study enrolled patients with peripheral artery disease who attended the outpatient cardiology clinic of the First Affiliated Hospital of Harbin Medical University between February and September 2016. All enrolled patients received optimized oral medical therapy in combination with a single session of SDT. Vascular evaluation was performed using color Doppler ultrasound before treatment and 1 and 4 weeks after treatment. The primary efficacy endpoint was the percent change from baseline in luminal diameter stenosis at the site of the atherosclerotic plaque (%Δ) at week 4, while the secondary efficacy endpoint was %Δ at week 1. Subgroup analyses were conducted according to prior statin use, plaque location, plaque characteristics, and baseline degree of luminal stenosis.Results:A total of 24 patients, aged (70.7±2.2) years were enrolled. There were 20 (83%) males. Compared to baseline, luminal diameter stenosis at the plaque site reduced by week 4 ((50.1±1.2)% vs. (57.2±1.1)%, P<0.001), %Δ was(12.32±1.05)%; and luminal diameter stenosis also reduced by week 1 ((51.7±1.2)% vs. (57.2±1.1)%, P<0.001)), %Δ was(9.61±0.85)%. In subgroup analyses, the treatment effect on diameter stenosis was independent of prior statin use; SDT reduced stenosis in both carotid and femoral plaques; with superior efficacy observed in hypoechoic and mixed-echo plaques; and efficacy was observed across mild, moderate, and severe baseline stenosis categories (all P<0.05). Conclusion:In this single-center pilot study, SDT demonstrates therapeutic efficacy across mild, moderate, and severe stenoses, as well as in hypoechoic and mixed-echo plaques, showing potential to rapidly promote luminal gain at carotid and femoral atherosclerotic plaque sites.

Objective:To preliminarily evaluate the lumen gain of sonodynamic therapy (SDT) mediated by sinoporphyrin sodium at carotid and femoral atherosclerotic plaque sites, and to assess whether concomitant statin use, lesion location, plaque echogenicity/type, and baseline stenosis severity modify the therapeutic response.Methods:This single-center, prospective, exploratory pilot clinical study enrolled patients with peripheral artery disease who attended the outpatient cardiology clinic of the First Affiliated Hospital of Harbin Medical University between February and September 2016. All enrolled patients received optimized oral medical therapy in combination with a single session of SDT. Vascular evaluation was performed using color Doppler ultrasound before treatment and 1 and 4 weeks after treatment. The primary efficacy endpoint was the percent change from baseline in luminal diameter stenosis at the site of the atherosclerotic plaque (%Δ) at week 4, while the secondary efficacy endpoint was %Δ at week 1. Subgroup analyses were conducted according to prior statin use, plaque location, plaque characteristics, and baseline degree of luminal stenosis.Results:A total of 24 patients, aged (70.7±2.2) years were enrolled. There were 20 (83%) males. Compared to baseline, luminal diameter stenosis at the plaque site reduced by week 4 ((50.1±1.2)% vs. (57.2±1.1)%, P<0.001), %Δ was(12.32±1.05)%; and luminal diameter stenosis also reduced by week 1 ((51.7±1.2)% vs. (57.2±1.1)%, P<0.001)), %Δ was(9.61±0.85)%. In subgroup analyses, the treatment effect on diameter stenosis was independent of prior statin use; SDT reduced stenosis in both carotid and femoral plaques; with superior efficacy observed in hypoechoic and mixed-echo plaques; and efficacy was observed across mild, moderate, and severe baseline stenosis categories (all P<0.05). Conclusion:In this single-center pilot study, SDT demonstrates therapeutic efficacy across mild, moderate, and severe stenoses, as well as in hypoechoic and mixed-echo plaques, showing potential to rapidly promote luminal gain at carotid and femoral atherosclerotic plaque sites.

Objective To observe the value of amide proton transfer(APT)imaging for assessing central nervous system damages in stable chronic obstructive pulmonary disease(COPD)and the correlations with MR spectroscopy(MRS)and lung function parameters.Methods Thirty-nine stable COPD patients(COPD group)and 34 healthy subjects(control group)were prospectively enrolled.Images of plain head MR,3D-APT and thalami MRS were acquired,and parameters of lung function were obtained.The basic data,outcomes of voxel-based morphometry(VBM)analysis,APT values in multiple brain regions and thalami MRS metabolite parameters were compared between groups,and the correlations of thalamus APT values with thalamus MRS metabolites parameters and lung function parameters were explored.Results Lung function parameters in COPD group were lower than those in control group,while cerebrospinal fluid volume(CSFV)and total brain volume(TIV)in COPD group were lager than those in control group(all P＜0.05).Compared with those in control group,APT values of bilateral thalami,right temporal lobe and right occipital lobe in COPD group were higher,and the peak value of N-acetyl aspartate(NAA)of bilateral thalami and NAA/creatin of right thalamus in COPD group were lower(all P＜0.05).Within COPD group,APT values of bilateral thalami were positively correlated(r=0.641),while APT values of left thalamus showed negative correlation(r=-0.435)with NAA values left thalamus and negative correlation(r=-0.432)with the forced expiratory volume in the first one second after bronchodilator administration(FEV1)(all P＜0.05).Conclusion APT values of central nervous system elevated and NAA values decreased in COPD patients.There were negative correlations between left thalamus APT and NAA values,also between APT values of left thalamus and FEV1.

Purpose The feasibility and application value of 3D amide proton transfer weighted(APTw)imaging is used to evaluate central nervous system injury in stable chronic obstructive pulmonary disease(COPD)patients.Materials and Methods A total of 36 COPD patients who attended the First Affiliated Hospital of Henan University of Chinese Medicine from January 2022 to August 2023 were selected along with 31 age-and gender-matched healthy volunteers.All subjects underwent pulmonary function tests,routine blood tests,Montreal cognitive assessment scale(MoCA)assessment and 3.0T MRI scan.The APT values of each brain region were measured independently and assessed for consistency by two observers,and the differences in APT values of each brain region were compared between the two groups to explore the correlation between the APT values of multiple brain regions and the pulmonary function,blood indices,and MoCA scores.Results The measurement consistency of APT values in multiple brain regions among observers was good(ICC>0.75).The APT values of brain regions in the COPD group were higher than those in the healthy control group,with statistically significant differences between the bilateral pallidum(t=2.490,2.168),the right thalamus(t=2.754),the nucleus accumbens(t=2.137),the temporal lobe gray matter(t=3.533)and the occipital lobe gray matter(t=2.345)compared with those in the healthy control group(all P<0.05);the APT values of the multiple brain regions were in a negative correlation(r=-0.390--0.084),with a stronger correlation between bilateral pallidum(r=-0.390,-0.370,both P<0.05);lung function indexes(forced vital capacity,forced expiratory volume in one second,forced expiratory volume in one second/forced vital capacity,forced expiratory volume in one second/prediction)in the COPD group showed a negative correlation trend with the APT values of the multibulbar areas(r=-0.339--0.010,all P>0.05),while white blood cell count,red blood cell count,hemoglobin concentration and platelet count showed a positive correlation trend with multi brain APT values(r=0.084-0.587).Conclusion As a novel MRI technology,APTw has potential application value in early detection of central nervous system damage in COPD patients and non-invasive monitoring of disease progression.

ObjectiveTo examine the clinical features of fractures and related risk factors in patients with rheumatoid arthritis(RA) in China.MethodsSix hundred and eighty-one RA patients were randomly selected from department of rheumatology of 18 hospitals of China.Data were obtained from the questionnaire,including age,sex,disease duration,the involvement of joints,treatment regimen,features of fractures etc.The possible risk factors of fracture in patients with RA were analyzed with a multi-variate Logistic regression analysis.Results① In 681 RA patients of the survey,48 patients had 54 fractures,and the incidence of fractures was about 8％.② Fractures occurred at various sites.Foot/ankle,femur,spine and wrist were the mostfrequent sites.③ The Logistic regression analysis showed that several factors increased the risk of fracture in RA patients,including long disease duration (OR:1.245,95％CI:0.987-1.570,P=0.065),male gender(OR:0.433,95％CI:0.199-0.942,P=0.035),more deformed joints(OR:1.042,95％CI:1.006-1.079,P=0.023),family history of RA (OR:2.201,95％CI:0.984-4.923,P=0.055),and high scores of SF-36(OR:1.017,95％CI:1.002-1.033,P=0.028).④ According to the degree of correlation from strong to weak,the risk factors of fracture were disease duration,SF-36,sex,number of deformed joints and family history of rheumatoid arthritis.ConclusionThe incidence of fracture is high in patients with rheumatoid arthritis.Several factors could increase the risk of fractures in RA patients,including long disease duration,male gender,more deformed joints,and family history of RA.In order to prevent the occurrence of fractures,cautions should be taken to prevent the development of fractures and treat the disease aggressively to suppress the disease activity of RA.

Objective To describe the distribution of medication costs of rheumatoid arthritis patients, and to analyze the factors that may affect the costs. Methods Data were obtained from a 12-month retrospective investigation of patients with rheumatoid arthritis (RA) across China. Department of Rheuma-tology of 18 hospitals were randomly selected. The data about their social conditions, clinical conditions, medications associated with RA such as disease-modifying antirheumatic drugs (DMARDs), non -steroidal anti -inflammtory drugs (NSAIDs), steroids, biologic agents were collected, and the costs of drugs were calculated. A non-parameter test and multivariate logistic regression analysis were performed. Results Six hundred and forty six patients were enrolled into the study, 435 completed data were chosen for analysis. The results demonstrated that the average costs per patient for medications in the past year was 8018 . The total medication costs were further subdivided into the following parts: DMARDs, (represented 20% of the total costs), biologic drugs (49%), NSAIDs (4%), herbal drugs (22%), steroids (1%). Data analysis showed that patients with higher education and higher incomes, with medical insurance,better health function status and outpatients paid more on DMARDs. Extra-articular manifestations increased the odds of the high-cost group (OR: 2.180, 95%CI: 1.335～3.558, P=0.002), while poor health function status increased the probability of paying high costs (OR: 1.373, 95%CI: 1.012～1.863, P=0.041). Conclusion High medication costs in RA do exist in RA patients. The costs of medication is associated with health function status and the presence of extra-articular manifestations.